Relmada Therapeutics Inc (NAS:RLMD)
$ 3.05 -0.06 (-1.93%) Market Cap: 92.03 Mil Enterprise Value: 10.23 Mil PE Ratio: 0 PB Ratio: 1.28 GF Score: 31/100

Q2 2023 Relmada Therapeutics Inc Earnings Call Transcript

Aug 08, 2023 / 08:30PM GMT
Release Date Price: $2.54 (-3.79%)
Operator

Greetings, and welcome to Relmada Therapeutics, Inc. Second Quarter 2023 Earnings Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Tim McCarthy, LifeSci Advisors. Please, Mr. Tim, go ahead.

Timothy McCarthy
LifeSci Advisors, LLC - MD & Relationship Manager

Thank you, operator, and thank you all for joining us this afternoon. With me on today's call are Chief Executive Officer, Sergio Traversa; and Chief Financial Officer, Maged Shenouda; and Dr. Cedric O'Gorman, Chief Medical Officer. This afternoon, Ramada issued a press release providing a business update announcing financial results for the 3 and 6 months ended June 30, 2023.

Please note that certain information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that during this call, Relmada's management team will be making forward-looking statements. Actual results could differ materially from those stated

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot